Home Cart Sign in  
Chemical Structure| 1043444-18-3 Chemical Structure| 1043444-18-3

Structure of Cl-amidine TFA
CAS No.: 1043444-18-3

Chemical Structure| 1043444-18-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cl-amidine is a peptidylarginine deminase (PAD) inhibitor, with an IC50 5.9±0.3 μM for PAD4.

Synonyms: Cl-amidine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cl-amidine TFA

CAS No. :1043444-18-3
Formula : C16H20ClF3N4O4
M.W : 424.80
SMILES Code : O=C(N)[C@@H](NC(C1=CC=CC=C1)=O)CCCNC(CCl)=N.O=C(O)C(F)(F)F
Synonyms :
Cl-amidine
MDL No. :MFCD31536783
InChI Key :WUSNMVYWOLUWDD-MERQFXBCSA-N
Pubchem ID :57402549

Safety of Cl-amidine TFA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Cl-amidine TFA

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CD68+VSMCs 100 μM 0.5 h Inhibit PAD4 activity, reduce ETs generation PMC9723654
HEK293T/PAD2 cells 25 μM 1 hour To evaluate the target engagement of Cl-amidine TFA in HEK293T/PAD2 cells, results showed that it effectively entered the cells and covalently modified PAD2 at 25 μM concentration. PMC5477668
NZM mouse neutrophils 200 μM 12 hours Cl-amidine inhibited NET release from NZM mouse neutrophils PMC3696545
BALB/c mouse neutrophils 200 μM 12 hours Cl-amidine inhibited NZM serum-induced NET release from BALB/c mouse neutrophils PMC3696545
keratinocytes 0–800 μM 2 days Cl-amidine inhibited deimination in a dose-dependent manner and was not cytotoxic for keratinocytes. At 800 μM, Cl-amidine was shown to reduce deimination by half, alter keratinocyte differentiation, decrease the number of corneocyte layers, significantly increase the number of transitional cells, induce clustering of mitochondria and of heterogeneous vesicles in the cytoplasm of granular keratinocytes, and upregulate the expression of autophagy proteins, including LC3-II, sestrin-2 and p62/SQSTM1. PMC6708725
Human brain microvascular endothelial cells (HBMVECs) 6 μM 24 hours To assess the direct effect of Cl-amidine on brain endothelial cell PADs, results showed no significant effect of Cl-amidine treatment on vWF release, indicating no citrullination in brain endothelial cells. PMC11634782
Human brain microvascular endothelial cells (HBMVECs) 500 ng/mL 24-72 hours To assess the effect of NETs on EndMT in brain endothelial cells, results showed that NETs promote EndMT, as evidenced by changes in cell morphology and increased Snail expression. PMC11634782
MCF7/TamR cells 200 μM 4 days To evaluate the inhibitory effect of Cl-amidine on the proliferation of MCF7/TamR cells, results showed that 200 μM Cl-amidine significantly inhibited cell proliferation PMC6785896
MCF7/TamR cells 50 μM 4 days To evaluate the inhibitory effect of Cl-amidine combined with tamoxifen on the proliferation of MCF7/TamR cells, results showed that 50 μM Cl-amidine combined with 5 μM tamoxifen significantly inhibited cell proliferation PMC6785896
MCF7/TamR cells 25 μM 4 days To evaluate the effect of Cl-amidine combined with docetaxel on the viability of MCF7/TamR cells, results showed that 0.1 μM docetaxel combined with 25 μM Cl-amidine significantly decreased cell viability PMC6785896
U2OS cells 20 μM 72 hours To evaluate the antiproliferative activities of Cl-amidine TFA analogs on U2OS cells. Results showed that biphenyl tetrazole tert-butyl Cl-amidine (13) completely abolished the growth of U2OS cells at 20 μM. PMC4610306

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NZM mice NZM mouse lupus model subcutaneous injection 10 mg/kg/d daily for 14 weeks Cl-amidine significantly improved vasculogenesis, endothelial function, and prothrombotic phenotype in NZM mice PMC3696545
Pad4−/− mice Citrobacter rodentium infection model Intraperitoneal injection 20 mg/kg Administered 3 hours prior to infection, followed by once daily for the next 3 consecutive days and then once every alternate day until day 11 Cl-amidine treatment modestly enhanced the susceptibility of WT mice to C. rodentium infection, as evidenced by increased CR burden in feces and worsened colonic histopathology, though to a lesser extent compared to Pad4?/? mice and DNase I-treated mice. PMC6519124
Mice Ccm3-iECKO mice Intraperitoneal injection 10 mg/kg/day Once daily for 7 days To assess the effect of Cl-amidine on NET formation and CCM lesions, results showed that Cl-amidine significantly reduced NET formation and lesion burden, improving endothelial activation, EndMT, coagulation, and neuroinflammation. PMC11634782
BALB/c Nude mice Breast cancer xenograft model Intraperitoneal injection 20 mg/kg/day Every 3 days for 3 weeks To evaluate the effect of Cl-amidine combined with docetaxel on tumor growth in a breast cancer xenograft model, results showed that the combination treatment significantly reduced tumor weight PMC6785896
C57BL/6 mice Traumatic brain injury model Intraperitoneal injection 10 mg/kg Once daily for three consecutive days Inhibition of PAD4 significantly ameliorated neurological deficits in mice and reduced neuronal pyroptosis by inhibiting the STING/IRE1α-NLRP1 pathway PMC10152368
C57BL/6J mice DSS-induced colitis model Gavage 25mg/kg Once daily for 7 days To evaluate the effect of Cl-amidine on DSS-induced colitis, the results showed that Cl-amidine alleviated the severity of colitis, reduced weight loss, decreased the disease activity index (DAI) score, and increased colon length. PMC10151647
C57BL/6 mice Traumatic brain injury (TBI) model Intraperitoneal injection 50 mg/kg Once daily for three consecutive days Cl-amidine treatment improved short-term neurological functions, reduced cerebral lesion volume, reduced brain edema, and restored cerebral blood flow (CBF) after TBI. In addition, Cl-amidine exerted neuroprotective effects by attenuating BBB disruption, inhibiting immune cell infiltration, and alleviating neuronal death after TBI. PMC10543875

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.35mL

0.47mL

0.24mL

11.77mL

2.35mL

1.18mL

23.54mL

4.71mL

2.35mL

References

 

Historical Records

Categories